Johnson & Johnson (JNJ) announced the FDA has approved a supplemental Biologics License Application to include evidence in the TREMFYA label for the inhibition of progression of structural joint damage in adults with active psoriatic arthritis. The company said the inclusion of this key outcome reflects that TREMFYA is the only IL-23 inhibitor proven to help stop further structural damage, offering patients with active PsA a first-line treatment option that provides effective symptom control and no new safety signals, while significantly inhibiting irreversible joint damage.
Brandee Pappalardo, Vice President, Medical Affairs, Dermatology & Rheumatology, Johnson & Johnson Innovative Medicine, said: "This label update reinforces our commitment to advancing innovation for these patients by offering the only IL-23 inhibitor with structural inhibition in its label, making TREMFYA a differentiated treatment option for symptom relief and joint preservation that helps address the progressive nature of active psoriatic arthritis."
At last close, Johnson & Johnson shares were trading at $230.80, down 0.21%.
For More Such Health News, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.